Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion
International Journal of Clinical Oncology · 2026-05 · 31 (5) · 890-898
DOI: 10.1007/s10147-026-03007-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 17.03.2026. Verfasst von Shunya Hanawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Musashino Red Cross Hospital, 1-26-1 Kyonan-Cho, Musashino-Shi, Tokyo, 180-8610, Japan. s.hanawa.1443@gmail.com. Hauptthemen laut MEDLINE: Pleural Effusion, Malignant, Pleurodesis, Talc. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Talc slurry pleurodesis is widely used for malignant pleural effusion (MPE); however, its success rate ranges from 50 to 75%, and reliable predictors are lacking. This study aimed to identify predictors of pleural effusion control failure following pleurodesis and develop a short-term predictive scoring system. METHODS: We retrospectively analyzed 170 patients with MPE who underwent talc pleurodesis at a single center between 2014 and 2024. The cohort was divided into training (n = 136) and validation (n = 34) cohorts. Logistic regression was used to identify independent predictors of pleural effusion control failure within 30-90 days. RESULTS: The most common primary tumors were lung, breast, and ovarian cancers. Pleural effusion was controlled in 70.6% of cases. Univariate analysis identified low body mass index, supportive care alone, Grade 2 collapse of the lower lung field post-drainage, extensive pulmonary consolidation, large tumor (≥ 7 cm), hypoalbuminemia, and positive pleural fluid cytology (Class III or higher) to be associated with pleural effusion control failure. Multivariate analysis revealed that massive pleural effusion (P = 0.048), supportive care alone (P < 0.001), and Grade 2 lung collapse (P = 0.003) were independent predictors of pleural effusion control failure. A scoring system incorporating these factors was validated in a validation cohort, demonstrating a control rate of approximately 90%, 60% and 30% in patients scoring ≤ 1, 2 and ≥ 3 points, respectively. CONCLUSIONS: The scoring system may support early decision-making regarding talc pleurodesis and palliative strategies, potentially improving quality of life in patients with MPE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Musashino Red Cross Hospital, 1-26-1 Kyonan-Cho, Musashino-Shi, Tokyo, 180-8610, Japan. s.hanawa.1443@gmail.com.
- Department of Respiratory Medicine, Musashino Red Cross Hospital, 1-26-1 Kyonan-Cho, Musashino-Shi, Tokyo, 180-8610, Japan. m.ejima245@gmail.com.
- Department of Respiratory Medicine, Musashino Red Cross Hospital, 1-26-1 Kyonan-Cho, Musashino-Shi, Tokyo, 180-8610, Japan.
Zitieren
APA
Hanawa, S., Ejima, M., Sugawara, M., Kubota, N., Kato, R., Hanawa, K., Higashi, S., Hanada, S., & Taki, R. (2026). Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion. International Journal of Clinical Oncology, 31(5), 890-898. https://doi.org/10.1007/s10147-026-03007-0
Vancouver
Hanawa S, Ejima M, Sugawara M, Kubota N, Kato R, Hanawa K, et al. Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion. International Journal of Clinical Oncology. 2026;31(5):890-898. doi:10.1007/s10147-026-03007-0
BibTeX
@article{Hanawa2026,
author = {Hanawa, Shunya and Ejima, Masaru and Sugawara, Mari and Kubota, Natsushi and Kato, Rina and Hanawa, Kotaro and Higashi, Seishi and Hanada, Satoko and Taki, Reiko},
title = {Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {5},
pages = {890--898},
doi = {10.1007/s10147-026-03007-0}
}
EUVIMED